53 results about "Mometasone" patented technology

A pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative, thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and a bulking agent having a mass median diameter of less than one micron.

A pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and a bulking agent having a mass median diameter of less than one micron.

The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the use of such compositions for prevention and treatment of dermal infections.

Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and / or hair), and can be used therapeutically for extended periods of time (e.g., greater than 3 weeks). Treatment with the composition of the present invention carries reduced and / or fewer side effects compared with commercially available mometasone furoate cream products. The cream composition of the present invention is safe for the use of babies and infants under 2 years old. Additionally provided are methods of preparing and using the composition of the invention.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

Disclosed is a novel mometasone furoate cream formulation for topical administration in a oleaginous base containing propylene glycol. This cream is a cosmetically elegant preparation of mometasone that is both stable and bioeffective.

A pharmaceutical composition comprising: (A) at least one compound of formula (I): wherein X is O or S, preferably O R6 is H, C1-6alkyl, —(CH2)pCOOH, —(CH2)pCOOC1-6alkyl, —(CH2)pCONH2, —(CH2)pCONHC1-6alkyl, —(CH2)pCON(C1-6alkyl)2, R11 is H or C1-6 alkyl; each R5 is —OC1-10alkyl, —SC1-10alkyl, —C1-12alkyl, or OAr2; wherein Ar2 is phenyl, optionally substituted with one or more halo; each p is 0 to 3; each z is 1 to 2; or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; and (B) one or more corticosteroid partners, preferably selected from the group consisting of betamethasone, clobetasol, halometasone, dexamethasone, fluocortolone, desoximetasone, diflorasone, fluocinonide, flurandrenolide, halobetasol, amcinonide, halocinonide, triamcinolone, hydrocortisone, aclometasone, fluticasone, mometasone, clocortolone, fluocinolone, desonide, prednisone, prednisolone, and prednicarbate or a pharmaceutically acceptable salt, or a hydrate or solvate thereof, especially betamethasone or a pharmaceutically acceptable salt, or a hydrate or solvate thereof.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

The present invention addresses the problem of providing, in order to treat dermatomycosis accompanying severe inflammations such as flare ups, an externally applied pharmaceutical composition which includes a combination of an anti-fungal agent and a steroidal agent, and in which the anti-fungal agent and the steroidal agent do not interfere with each other. This externally applied pharmaceutical composition for treating mycosis is characterized by including: a compound represented by general formula (1) shown below (in general formula (1), R represents hydrogen or a halogen, and X represents a halogen), and / or a salt thereof; and a steroid selected from prednisolone, dexamethasone, hydrocortisone, clobetasone, clobetasol, betamethasone, and mometasone.

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

The invention provides application of nitrogenous bisphosphonate combined glucocorticoid in prevention or treatment of viral pneumonia. In particular, the nitrogenous bisphosphonate combined glucocorticoid is used to treat or ameliorate coronavirus infections, wherein the nitrogen-containing bisphosphonate is selected from pamironate, alendronate, risedronate, ibandronate, zoledronate, minodronate and pnaphonate, and the glucocorticoid is selected from the group consisting of dexamethasone, rimesolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunivoxone, antiphlogistic, fluticasone propionate, beclomethasone dipropionate, budesonide and mometasone furoate.

A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.

Disclosed are compositions comprising topical corticosteroids, such as fluticasone and mometasone, and a biopolymer in a cream base, wherein the cream base comprises a primary and a secondary emulsifier, a waxy material, a co-solvent, a preservative, an acid, a chelating agent, a penetration enhancer, a buffering agent, and water. The biopolymer comprises chitosan. The compositions disclosed herein are suitable for the treatment of dermatological conditions including but not limited to healing wounds and treatment of dermatitis.

The invention provides a method for preparing a steroid drug intermediate with 16-alpha-methyl. In the method, a steroid compound I is selected as an initiator to take part in Grignard reaction to transform the sixteenth bit thereof so as to obtain a Grignard product; the Grignard product takes part in epoxy reaction to transform the seventeenth bit thereof to obtain a Grignard epoxy product; and the Grignard epoxy product takes part in hydrolysis reaction to transform the third bit thereof and perform open loop on the seventeenth bit and the twentieth bit thereof to obtain a steroid compound II which is the steroid drug intermediate with 16-alpha-methyl. The steroid compound II with 16-alpha-methyl is usually used for preparing common clinical meqoeofrol acefate, such as dexamethasone, dexamethasone sodium phosphate, mometasone furoate, dexamethasone acetate and the like.

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.

The present application provides a novel combination preparation for use in the treatment of acute, chronic and allergic rhinosinusitis and / or allergic rhinitis which does not cause dry nasal mucosa and is very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient in the form of a nasal spray.

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

The invention discloses high-stability mometasone furoate emulsifiable paste and a processing technology thereof, and relates to the technical field of emulsifiable paste preparations. A double-emulsification-system preparation process is adopted, the stability of the cream is remarkably improved, firstly, main drug active ingredients are prepared into submicron emulsion through dispersion and homogenization to form a first emulsification system (W / O) to play a role in primary protection, secondly, dispersion is added into a water phase to form an oil-in-water particle structure, and then the dispersion and an oil phase are emulsified to form a second emulsification system (O / W / O) to play a role in secondary protection. The mometasone furoate emulsifiable paste with high stability is prepared by adding auxiliary materials such as titanium dioxide and starch aluminum octenylsuccinate, so that the bioavailability of mometasone furoate is improved; by cooperating with excellent oxidation resistance of 4-vinyl guaiacol, gallic acid and glycyrrhizic acid, the oxidation resistance of the cream is remarkably improved, and the long-acting stability of the cream is further ensured.

Disclosed is a novel pharmaceutical composition for treating ear infections in animals in a single dose, wherein the pharmaceutical composition comprises a gentamicin antibiotic, a posaconazole antifungal drug, and a mometasone anti-inflammatory drug.

The invention describes a pharmaceutical composition. The pharmaceutical composition comprises a drug component consisting of at least one mometasone compound selected from mometasone and mometasone furoate; and a propellant component, wherein at least 90 weight % of the propellant component is 1,1-difluoroethane (R-152a), and wherein the mometasone compound is the only drug component in the composition.

The present application provides a novel combination preparation for us in the treatment of acute, chronic and allergic rhinosinusitis which does not cause dry nasal mucosa and is nevertheless very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.